126 related articles for article (PubMed ID: 15880133)
21. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
22. Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation.
Parkins MD; Bahlis N; Brown C; Savoie L; Chaudhry A; Russell JA; Stewart DA
Bone Marrow Transplant; 2006 Nov; 38(9):609-14. PubMed ID: 16980991
[TBL] [Abstract][Full Text] [Related]
23. A comparison of actual registered costs and costs derived from diagnosis-related groups (DRGs) for patients undergoing heart transplantation, lung transplantation, and thoracotomy for other lung diseases.
Mishra V; Skeie B; Vaaler S; Amlie E
Transpl Int; 2001 Dec; 14(6):361-9. PubMed ID: 11793033
[TBL] [Abstract][Full Text] [Related]
24. Mobilization of peripheral blood stem cells for autologous transplantation patients with hematological malignancies: Influence of disease, mobilization method, age and sex.
Zhang C; Chen X; Zhang X; Gao L; Kong P; Wang Q; Peng X; Liu H
Transfus Apher Sci; 2008 Aug; 39(1):21-8. PubMed ID: 18599353
[TBL] [Abstract][Full Text] [Related]
25. Optimization of CD34+ collection for autologous transplantation using the evolution of peripheral blood cell counts after mobilization with chemotherapy and G-CSF.
Delamain MT; Metze K; Marques JF; Reis AR; De Souza CA; Lorand-Metze I
Transfus Apher Sci; 2006 Feb; 34(1):33-40. PubMed ID: 16376618
[TBL] [Abstract][Full Text] [Related]
26. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer.
De Rosa L; Lalle M; Pandolfi A; Pescador L
Bone Marrow Transplant; 2001 May; 27(10):1031-5. PubMed ID: 11438817
[TBL] [Abstract][Full Text] [Related]
27. Health-related quality of life in multiple myeloma survivors treated with high dose chemotherapy followed by autologous peripheral blood progenitor cell transplantation: a retrospective analysis.
Slovacek L; Slovackova B; Pavlik V; Hrstka Z; Macingova Z; Jebavy L; Horacek JM
Neoplasma; 2008; 55(4):350-5. PubMed ID: 18505348
[TBL] [Abstract][Full Text] [Related]
28. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study.
Blommestein HM; Verelst SG; Huijgens PC; Blijlevens NM; Cornelissen JJ; Uyl-de Groot CA
Ann Hematol; 2012 Dec; 91(12):1945-52. PubMed ID: 22864761
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma.
Kroschinsky F; Hölig K; Platzbecker U; Poppe-Thiede K; Ordemann R; Blechschmidt M; Oelschlaegel U; Schaich M; Hänel M; Bornhäuser M; Ehninger G
Transfusion; 2006 Aug; 46(8):1417-23. PubMed ID: 16934080
[TBL] [Abstract][Full Text] [Related]
30. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
Ozdogu H; Boga C; Kizilkilic E; Kozanoglu I; Karakus S; Sahin FI; Unalan D; Haberal M
Transplant Proc; 2007 May; 39(4):1257-60. PubMed ID: 17524948
[TBL] [Abstract][Full Text] [Related]
31. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
32. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
34. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey.
Pierelli L; Berto P; Accorsi P; Milone G; Lopatriello S; Aiello A; Iacopino P; Olivieri A; Rambaldi A; Bosi A
Transfus Apher Sci; 2013 Dec; 49(3):615-22. PubMed ID: 23973731
[TBL] [Abstract][Full Text] [Related]
35. The immature reticulocyte fraction: a negative predictor of the harvesting of CD34 cells for autologous peripheral blood stem cell transplantation.
Dunlop LC; Cohen J; Harvey M; Gallo J; Motum P; Rosenfeld D
Clin Lab Haematol; 2006 Aug; 28(4):245-7. PubMed ID: 16898963
[TBL] [Abstract][Full Text] [Related]
36. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
37. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma.
Arango JI; Restrepo A; Schneider DL; Callander NS; Ochoa-Bayona JL; Restrepo MI; Bradshaw P; Patterson J; Freytes CO
Bone Marrow Transplant; 2006 Mar; 37(5):517-21. PubMed ID: 16435018
[TBL] [Abstract][Full Text] [Related]
38. Comparison of peripheral blood progenitor cell yield from standard chemotherapy used in the treatment of lymphoid malignancies and high-dose cyclophosphamide: a retrospective review of 141 patients.
Assouline S; Sylvestre MP; Carriere P; Shustik C; Laneuville P
Transfusion; 2006 Feb; 46(2):174-9. PubMed ID: 16441591
[TBL] [Abstract][Full Text] [Related]
39. Costs of payment in Thai acute coronary syndrome patients.
Moleerergpoom W; Kanjanavanit R; Jintapakorn W; Sritara P
J Med Assoc Thai; 2007 Oct; 90 Suppl 1():21-31. PubMed ID: 18431883
[TBL] [Abstract][Full Text] [Related]
40. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen.
Dawson MA; Schwarer AP; Muirhead JL; Bailey MJ; Bollard GM; Spencer A
Bone Marrow Transplant; 2005 Sep; 36(5):389-96. PubMed ID: 15980882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
